Logo

Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

Share this
Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

Shots:

  • The approval is based on P-III ESAX-HTN study assessing esaxerenone vs eplerenone for 12wks. in patients with essential hypertension- 1EP as SBP / DBP
  • In 2006- Exelixis and Daiichi Sankyo collaborated to develop and commercialize and Esaxerenone tablets. Exelixis will receive $20M milestone on sales and has received additional $20M as on regulatory milestones in Q1’18
  • Minnebro tablets (1.25/2.5/5 mg) are antihypertensives drug used for blocking mineralocorticoid receptor activation and is evaluated in P-III for diabetic nephropathy by Daiichi

Ref: Exelixis | Image: Daiichi Sankyo


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions